AFP and hepatocellular carcinoma: Importantly, triFc_AGP can identify a number of AFP-negative HCC patients, where the ROC analysis showed that the combination of triFc_AGP and AFP can significantly improve the specificity for AFP-negative HCC patients to 85% compared to AFP alone (65%), using the optimal cutoffs.